

MITRE / FLUX NOTES **TREATMENT OPTIONS v5.1**

EDWIN CHOI, DANIEL REEVES, JUHAN SONIN, 19.DEC.2018 



Summary

Treatment
Options

Treatment Options Ductal carcinoma of the breast

Outcomes and criteria for 156,765 patients with Ductal carcinoma of the breast were collected by CancerLinQ [...more](#)

> Similar patients 156 patients

excluded criteria: race, received radiation therapy, received chemotherapy

> Outcomes overall survival rate, ECOG impact, hospitalization due to side effects

		Overall survival rates			ECOG impact	Hospitalization due to side effects	
		1 yr	2 yr	5 yr		all	leading causes
include only: add/remove							
surgery	(11)	67% 	54% 	43% 	0.2	19%	pain (9%) neuropathy (4%)
combine with: select treatments							
hormonal therapy & chemotherapy	(64)	87% ▲20% 	74% ▲20% 	58% ▲15% 	0.5 ▲0.3	15% ▼4%	pain (9%) dyspnoea (2%)
hormonal therapy	(76)	77% ▲10% 	59% ▲5% 	49% ▲6% 	0.5 ▲0.3	23% ▲4%	dyspnoea (11%) blood clots (4%)
chemotherapy	(12)	68% ▲1% 	53% ▼1% 	41% ▼2% 	0.9 ▲0.7	22% ▲3%	pain (11%) dyspnoea (7%)



Summary

Treatment
Options


Treatment Options Ductal carcinoma of the breast

Outcomes and criteria for 156,765 patients with Ductal carcinoma of the breast were collected by CancerLinQ [...more](#)

> Similar patients 156 patients

excluded criteria: race, received radiation therapy, received chemotherapy

> Outcomes overall survival rate, ECOG impact, hospitalization due to side effects





Summary

Treatment Options

Treatment Options Ductal carcinoma of the breast

Outcomes and criteria for 156,765 patients with Ductal carcinoma of the breast were collected by CancerLinQ [...more](#)

> Similar patients 156 patients

excluded criteria: race, received radiation therapy, received chemotherapy

> Outcomes overall survival rate, ECOG impact, hospitalization due to side effects

		Overall survival rates			ECOG impact	Hospitalization due to side effects	
		1 yr	2 yr	5 yr		all	leading causes
include only: add/remove							
surgery	(11)	67% 	54% 	43% 	0.2	19%	pain (9%) neuropathy (4%)

combine with: [select treatments](#)

In combination with surgery:

compare across categories

☒ treatment categories

- ☐ surgery
- ☒ hormonal therapy
- ☒ chemotherapy
- ☐ radiation

compare within a category

- ☐ chemotherapy regimens
- ☐ hormonal therapy regimens
- ☐ radiation therapies

87% ▲20% 	74% ▲20% 	58% ▲15% 	0.5 ▲0.3	15% ▼4%	pain (9%) dyspnoea (2%)
77% ▲10% 	59% ▲5% 	49% ▲6% 	0.5 ▲0.3	23% ▲4%	dyspnoea (11%) blood clots (4%)
68% ▲1% 	53% ▼1% 	41% ▼2% 	0.9 ▲0.7	22% ▲3%	pain (11%) dyspnoea (7%)

survived with surgery alone
 additional survivors due to treatment
 cancer related deaths
 deaths due to other causes



Summary

Treatment
Options

Treatment Options Ductal carcinoma of the breast

Outcomes and criteria for 156,765 patients with Ductal carcinoma of the breast were collected by CancerLinQ [...more](#)

> Similar patients 156 patients

excluded criteria: race, received radiation therapy, received chemotherapy

> Outcomes overall survival rate, ECOG impact, hospitalization due to side effects

		Overall survival rates			ECOG impact	Hospitalization due to side effects	
		1 yr	2 yr	5 yr		all	leading causes
include only: add/remove							
surgery	(11)	67% 	54% 	43% 	0.2	19%	pain (9%) neuropathy (4%)

combine with: [select treatments](#)

hormonal therapy & chemotherapy	(64)	87% 	74% 	58%
hormonal therapy	(76)	77% 	59% 	49%
		8% 	53% 	41%

add to "include only:" list

remove from comparisons

compare across hormonal therapies

survived with surgery alone
 additional survivors due to treatment
 cancer related deaths
 deaths due to other causes

Surgery

19% All hospitalization due to side effects

9%	pain	Generalized pain
4%	neuropathy	A description of neuropathy that is ten words or less
3%	dyspnoea	A description of dyspnoea that cannot fit on this line and requires... more
2%	bleeding	Another description.
1%	other	



Summary

Treatment
Options

Treatment Options Ductal carcinoma of the breast

Outcomes and criteria for 156,765 patients with Ductal carcinoma of the breast were collected by CancerLinQ [...more](#)

Similar patients 156 patients

excluded criteria: race, received radiation therapy, received chemotherapy

[select all](#) [select none](#)

demographic 3/4

- ☒ age: 41-61
- ☒ age
- ☐ race
- ☒ sex:

genetics

- ☒ BRC
- ☒ BRA

pathology 5/5

- ☒ ER: negative

treatment history 1/3

- ☒ had surgery: yes
- ☐ received radiation therapy: yes
- ☐ received chemotherapy: yes

medical history 1/1

- ☒ ECOG score: 2-3

age (years)

[reset to +/- 10](#)

50

60

56

Outcomes overall survival rate, ECOG impact, hospitalization due to side effects

survival rates

- ☐ Relative survival rate [textual description](#)
- ☐ Cancer specific survival rate [textual description](#)
- ☐ Disease free survival rate [textual description](#)
- ☒ Total survival rate [textual description](#)

impact on quality of life indices

- ☐ Quality of Life-Cancer Survivor [textual description](#)
- ☐ ECOG Performance Status [textual description](#)
- ☐ Karnofsky Score [textual description](#)

side effects

- ☒ Hospitalizations due to side effects [textual description](#)
- ☐ Most severe side effects [textual description](#)
- ☐ Most common side effects [textual description](#)

costs

- ☐ Days expended [textual description](#)
- ☐ Out-of-pocket cost [textual description](#)
- ☐ Hospital stays [textual description](#)

Additional visualization modes (draft ideas)

to supplement the the default tabular view

These alternative views would not have the interactive methods of changing the included list and comparing list. A pair of separate dropdowns would be necessary.

Here we present narrative and chart views.

1 yr

2 yr


5 yr



With **surgery alone**, 68% of patients will survive 1 year, with 30% dying due to cancer. 10% are hospitalized due to side effects, most commonly due to **pain**.

With **chemotherapy** in addition to surgery, 5% **additional** patients will survive 1 year. 2% **more** are hospitalized due to side effects, most commonly due to **neuropathy**.


With **chemotherapy & radiation** in addition to surgery, 12% **additional** patients will survive 1 year. 4% **more** are hospitalized due to side effects, most commonly due to **blood clots**.



Additional visualization modes (draft ideas)

to supplement the the default tabular view

This chart compares treatments across two variables, relative to surgery alone. We compare impact on survival rate for 3 time points and quality of life.




Additional visualization modes (draft ideas)

to supplement the the default tabular view
This includes distribution data for one of the variables.



increase in
total survival
rate,
relative surgery
alone



Increase in quality of life impact, as ACOG, relative surgery alone

Additional visualization modes (draft ideas)

to supplement the the default tabular view

This visual shows expected outcomes for a statistical 100 patients. It graphically shows how many patients who would die without additional treatment survive with various treatments.

The user can tap on a treatment regimen to focus on that treatment and reveal additional data, such as hospitalization rates.

